Nurix Therapeutics (NRIX) Share-based Compensation (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Share-based Compensation data on file, last reported at $18.1 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 74.02% year-over-year to $18.1 million in Q2 2026; TTM through May 2026 was $1.7 million, a 95.31% decrease from a year earlier, with the FY2025 full-year figure at $20000.0, down 99.94% from the prior year.
• Share-based Compensation for Q2 2026 stood at $18.1 million, up from $2.7 million in the prior quarter.
• Over the last five years, Share-based Compensation for NRIX reached as high as $85.9 million in Q3 2022 and fell as low as -$28.9 million in Q4 2025.
• Historically, Share-based Compensation has averaged $15.4 million across 5 years, with a median of $8.8 million in 2024.
• On a YoY basis, Share-based Compensation climbed as much as 38356.52% in 2024 and fell as far as 61580.0% in 2024.
• Year by year, Share-based Compensation stood at $28.1 million in 2022, then advanced by 19.44% to $33.6 million in 2023, then slipped by 2.88% to $32.6 million in 2024, then slumped by 188.44% to -$28.9 million in 2025, then surged by 162.62% to $18.1 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $18.1 million in Q2 2026, $2.7 million in Q1 2026, and -$28.9 million in Q4 2025.